Alcohol dehydrogenase-1B represses the proliferation, invasion and migration of breast cancer cells by inactivating the mitogen-activated protein kinase signalling pathway.

Breast cancer (BRCA) is a serious life-threatening cancer, especially triple-negative breast cancer (TNBC). Alcohol dehydrogenase-1B (ADH1B) has recently been revealed to be associated with poor prognosis of BRCA patients. This study identified the exact function of ADH1B on the progression of BRCA and TNBC. ADH1B effect on the prognosis of BRCA and TNBC patients was researched based on online databases and clinical samples. The function of ADH1B on the proliferation, invasion and migration, and growth of BRCA and TNBC cells was investigated by cell counting kit-8, Transwell, and in vivo assays. Western blot was utilized to determine the effect of ADH1B on the mitogen-activated protein kinase (MAPK) signalling pathway activity. As a result, ADH1B was down-regulated in BRCA and TNBC patients and cells, predicting unfavorable prognosis (P<0.05). ADH1B overexpression suppressed the proliferation, invasion and migration, and inactivated the MAPK signalling pathway in BRCA and TNBC cells (P<0.01). ADH1B synergized with Selumetinib (inhibitor of the MAPK signalling pathway) to attenuate the proliferation, invasion and migration of BRCA and TNBC cells (P<0.001). Conversely, Vacquinol-1 (activator of the MAPK signalling pathway) abolished the suppression of ADH1B on the proliferation, invasion and migration of BRCA and TNBC cells (P<0.05). ADH1B suppressed in vivo growth of TNBC cells (P<0.001). Thus, ADH1B may inhibit the proliferation, invasion and migration of BRCA and TNBC cells by inactivating the MAPK signalling pathway. It may be a promising target for the clinical treatment of BRCA and TNBC.

Symptomatic Diethylene Glycol Ingestion Successfully Treated with Fomepizole Monotherapy.

BACKGROUND: Diethylene glycol (DEG) is an industrial solvent with many uses, including brake fluids. It has also caused mass poisonings after use as an inappropriate substitute for propylene glycol or glycerin, though individual ingestions are rare. Like other toxic alcohols, DEG is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase, with toxicity likely mediated by the resulting metabolites. Fomepizole, an alcohol dehydrogenase inhibitor, is used to prevent metabolite formation with other toxic alcohol exposures. Fomepizole is recommended for DEG poisoning, though supporting clinical evidence is limited. CASE REPORT: A 31-year-old man presented after ingestion of DEG-containing brake fluid and hydrocarbon-containing "octane booster." He was noted to be clinically intoxicated, with a mildly elevated anion gap metabolic acidosis and no osmolar gap. DEG level was later found to be elevated, consistent with his ingestion. He was treated with fomepizole alone, with resolution of metabolic acidosis and clinical findings over the next 2 days. No delayed neurologic sequelae were present at 52-day follow-up. Our case provides additional evidence supporting the use of fomepizole for DEG poisoning. Consistent with other toxic alcohols, DEG poisoning, especially early presentations, may benefit from empiric fomepizole administration. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: DEG poisoning is potentially life threatening, but treatable if identified early. An ingestion can be toxic despite a normal osmolar gap, leading to false reassurance. Finally, it is rare, so emergency physicians must be made aware of its potential dangers.

Functionalized Allopurinols Targeting Amyloid-Binding Alcohol Dehydrogenase Rescue Aß-Induced Mitochondrial Dysfunction.

Alzheimer's disease (AD) is the most common dementia affecting one in nine people over 65. Only a handful of small-molecule drugs and the anti-ß amyloid (Aß) antibody aducanumab are approved to treat AD. However, they only serve to reduce symptoms of advanced disease. Novel treatments administered early in disease progression before the accumulation of Aß and tau reaches the threshold where neuroinflammation is triggered and irreversible neuronal damage occurs are more likely to provide effective therapy. There is a growing body of evidence implying that mitochondrial dysfunction occurs at an early stage of AD pathology. The mitochondrial enzyme amyloid-binding alcohol dehydrogenase (ABAD) binds to Aß potentiating toxicity. Moreover, ABAD has been shown to be overexpressed in the same areas of the brain most affected by AD. Inhibiting the Aß-ABAD protein-protein interaction without adversely affecting normal enzyme turnover is hypothesized to be a potential treatment strategy for AD. Herein, we conduct structure-activity relationship studies across a series of functionalized allopurinol derivatives to determine their ability to inhibit Aß-mediated reduction of estradiol production from ABAD. The lead compound resulting from these studies possesses potent activity with no toxicity up to 100 µM, and demonstrates an ability to rescue defective mitochondrial metabolism in human SH-SY5Y cells and rescue both defective mitochondrial metabolism and morphology ex vivo in primary 5XFAD AD mouse model neurons.

Treating ethylene glycol poisoning with alcohol dehydrogenase inhibition, but without extracorporeal treatments: a systematic review.

CONTEXT: Ethylene glycol is metabolized to toxic metabolites that cause acute kidney injury, metabolic acidemia, and death. The treatment of patients with ethylene glycol poisoning includes competitively inhibiting alcohol dehydrogenase with ethanol or fomepizole to prevent the formation of toxic metabolites, and extracorporeal treatments such as hemodialysis to remove ethylene glycol and its metabolites. In the absence of significant metabolic acidemia or kidney injury, it is hypothesized that extracorporeal treatments may be obviated without adverse outcomes to the patient if alcohol dehydrogenase inhibitors are used. OBJECTIVES: The objectives of this study are to: (1) identify indicators predicting ADH inhibitor failure in patients with ethylene glycol poisoning treated with either ethanol or fomepizole for whom extracorporeal treatment was not performed (aside from rescue therapy, see below) (prognostic study), and (2) validate if the anion gap, shown in a previous study to be the best surrogate for the glycolate concentration, is associated with acute kidney injury and mortality (anion gap study). METHODS: We conducted a systematic review to identify all reported patients with ethylene glycol poisoning treated without extracorporeal treatments but with either fomepizole (fomepizole monotherapy) or ethanol (ethanol monotherapy). Analyses were performed using both one case per patient and all cases (if multiple events were reported for a single patient). Data were compiled regarding poisoning, biochemistry, and outcomes. Treatment failure was defined as mortality, worsening of acid-base status, extracorporeal treatments used as rescue, or a worsening of kidney or neurological function after alcohol dehydrogenase inhibition was initiated. Also, we performed an analysis of previously described anion gap thresholds to determine if they were associated with outcomes such as acute kidney injury and mortality. RESULTS: Of 115 publications identified, 96 contained case-level data. A total of 180 cases were identified with ethanol monotherapy, and 231 with fomepizole monotherapy. Therapy failure was noted mostly when marked acidemia and/or acute kidney injury were present prior to therapy, although there were cases of failed ethanol monotherapy with minimal acidemia (suggesting that ethanol dosing and/or monitoring may not have been optimal). Ethylene glycol dose and ethylene glycol concentration were predictive of monotherapy failure for ethanol, but not for fomepizole. In the anion gap study (207 cases), death and progression of acute kidney injury were almost nonexistent when the anion gap was less than 24 mmol/L and mostly observed when the anion gap was greater than 28 mmol/L. CONCLUSION: This review suggests that in patients with minimal metabolic acidemia (anion gap <28 mmol/L), fomepizole monotherapy without extracorporeal treatments is safe and effective regardless of the ethylene glycol concentration. Treatment failures were observed with ethanol monotherapy which may relate to transient subtherapeutic ethanol concentrations or very high ethylene glycol concentrations. The results are limited by the retrospective nature of the case reports and series reviewed in this study and require prospective validation.

Intoxicació per consum lúdic de metanol en sis adolescents / Intoxicación por consumo lúdico de metanol en seis adolescentes / Poisoning due to recreational use of methanol in six adolescents

Introducció: la intoxicació per metanol és rara en pediatria icomporta una elevada morbimortalitat. El metanol és un alcohol utilitzat com a dissolvent. El seu ús fraudulent en mesclesde begudes alcohòliques és la principal forma d'intoxicació. Observació clínica: es presenta una sèrie de sis casosd'adolescents amb intoxicació per metanol amb finalitat lúdica. Dos casos van presentar clínica gastrointestinal ineurològica, els altres es van mantenir asimptomàtics. Esva detectar acidosi metabòlica amb anió gap elevat i ambnivells de metanol detectable en tres casos; aquests vanrebre tractament amb etanol i bicarbonat endovenós, i dosvan necessitar, a més, hemodiàlisi. Comentaris: la intoxicació per metanol ha de formar partdel diagnòstic diferencial de l'acidosi metabòlica amb aniógap elevat. El seu diagnòstic i tractament precoç és essencial, tenint en compte la gravetat del quadre i el risc de seqüeles neurològiques, com ara la ceguesa. L'administracióde bicarbonat i de l'antídot (etanol o fomepizole), i l'hemodiàlisi constitueixen les eines terapèutiques principals

Introducción. La intoxicación por metanol es rara en pediatría y conlleva una elevada morbimortalidad. El metanol es un alcohol usado como disolvente. Su uso fraudulento en mezclas de bebidas alcohólicas es la principal forma de intoxicación. Observación clínica. Describimos una serie de seis casos de adolescentes con intoxicación por metanol con finalidad lúdica. Dos casos presentaron clínica gastrointestinal y neurológica, el resto permanecieron asintomáticos. Se detectó acidosis metabólica con anión gap elevado y con niveles de metanol detectable en tres casos; éstos recibieron tratamiento con etanol y bicarbonato endovenoso, dos de estos casos requirieron, además, hemodiálisis. Comentarios. La intoxicación por metanol debe formar parte del diagnóstico diferencial de la acidosis metabólica con anión gap elevado. Su diagnóstico y tratamiento precoz es esencial, dada la gravedad del cuadro y el riesgo de secuelas neurológicas, como la ceguera. La administración de bicarbonato y del antídoto (etanol o fomepizol), y la hemodiálisis constituyen las principales herramientas terapéuticas (AU)

Introduction. Methanol poisoning is a rare occurrence in children, and it is associated with high morbidity and mortality. Methanol is an alcohol used as solvent; its fraudulent use in mixtures of alcoholic beverages is the main form of poisoning. Case reports. We describe a series of six teenagers with poisoning due to recreational ingestion of methanol. Two cases had neurological and gastrointestinal symptoms, and the others remained asymptomatic. Metabolic acidosis with high anion gap and high levels of methanol was detected in three cases, which were treated with ethanol and intravenous bicarbonate; two of them also required hemodialysis. Comments. Methanol poisoning should be part of the differential diagnosis of metabolic acidosis with elevated anion gap. Early diagnosis and treatment are critical due to the potential severity of symptoms and risk of neurological consequences such as blindness. The administration of bicarbonate, the antidote (ethanol or fomepizole), and hemodialysis, are the main therapeutic tools (AU)

Experiments on alcocytes containing enzyme nanoparticles for reducing toxic blood concentration of ethanol.

We developed a method of introduction of alcohol dehydrogenase and aldehyde dehydrogenase into mouse and human erythrocytes. The possibility of using erythrocytes loaded with the two enzymes (alcocytes) for reducing ethanol concentration in animal blood was studied. Injection of alcocytes to mice led to accelerated decrease in ethanol concentration as soon as after 5 min and this capacity of alcocytes persisted for at least 2 h. Alcocytes prepared from fresh or preserved human blood did not survive in mice. Thus autologous alcocytes is functionally active and can be used as a protective system in acute alcohol intoxication. The developed method can be regarded as a new medical biotechnology.

In vitro study of alcohol dehydrogenase and acetaldehyde dehydrogenase encapsulated into human erythrocytes by an electroporation procedure.

The optimal conditions for electroporated/resealed loading of alcohol dehydrogenase (ADH) and/or acetaldehyde dehydrogenase (ALDH) into human erythrocytes were established prior to the study, with the following characteristics: 300 V, 1 ms pulse time, eight pulses every 15 min and 1 h resealing at 37 degreesC. High encapsulation yield and carrier cell recoveries were achieved. Cell volumes increase while hemoglobin contents decrease; in consequence a decrease in cell hemoglobin concentration was observed. A lower hypotonic resistance of loading erythrocytes (throughout osmotic fragility curves) and unaltered oxygen transport capability (as given by oxygen equilibrium curves) were observed. The stability against time (up to 168 h-7 days) of encapsulated individual enzymes, either ADH- or ALDH-red blood cells (RBCs), was studied at 4 degreesC and 37 degreesC, in comparison with that of free enzyme solutions. Both enzymes were released from carrier RBCs to the incubation medium. The stability of carrier RBCs was studied under similar conditions. Non-significant variations in hematological parameters were observed. However, the hemoglobin derivative forms showed modifications. The continuous degradation of ethanol by ADH-RBCs and coencapsulated ADH- and ALDH-RBCs, as a function of time (up to 70 h) suggests the use of these carrier RBCs as agents for complete metabolization of ethanol. The mentioned properties bare the possibility of using ADH and ALDH as carrier systems in in vivo situations.